Despite applying tax waivers to ease Nigeria’s drug crisis at the level of importation of key production ingredients like APIs, drug prices remain stubbornly high as loopholes and bureaucratic hurdles in implementation prevail. Yet, Nigeria is on the cusp of reintroducing tax breaks in a fresh
```
Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```

Join BusinessDay whatsapp Channel, to stay up to date

Open In Whatsapp